抗CGRPモノクローナル抗体による初期治療中の24時間ホルターモニタリングで血圧上昇は認められない:前向き観察研究 (SAFHYPER)
Flavia Lo Castro1, Niccolò Bonini2,3, Luigi Francesco Iannone1,3
1Digital and Predictive Medicine, Pharmacology and Clinical Metabolic Toxicology-Headache Center and Drug Abuse-Laboratory of Clinical Pharmacology and Pharmacogenomics, AOU Policlinico di Modena, Modena, Italy.
European journal of neurology
|September 6, 2025
まとめ
抗カルシトニン遺伝子関連ペプチド (CGRP) モノクローナル抗体 (mAbs) は,片頭痛患者の短期的な心血管安全性を示しています. 早期治療は血圧を有意に上昇させず,夜間浸水パターンを改善しませんでした.
科学分野:
- 心血管科学
- 神経学
- 薬理学について
背景:
- 片頭痛は高血圧を含む心血管疾患のリスクの増加と関連しています.
- 抗カルシトニン遺伝子関連ペプチド (CGRP) モノクローナル抗体 (mAbs) は,片頭痛予防に有効である.
- 抗CGRP mAbsの潜在的高血圧効果については懸念がある.
研究 の 目的:
- 偏頭痛患者の抗CGRP mAb治療中の早期の血圧の変化を評価する.
- 初期治療段階で抗CGRPmAbsの心血管安全性を評価する.
主な方法:
- 20人のエピソード性片頭痛 (EM) 患者を対象に実施された前向きな実用的な研究です.
- 最初の抗CGRP mAb注射の24時間前と4週間後のホルター血圧モニタリング
- 主要アウトカム: 平均シストリックBP (SBP) の変化 副次アウトカム: ダイアストリックBP (DBP),昼間/夜間BP,心拍数 (HR),浸水パターン
主要な成果:
- 24時間の平均SBP (−2. 4mmHg) やDBP (−1. 8mmHg) の有意な変化はありません.
- 夜間DBPの有意な減少 (-2. 6mmHg,p=0. 026) と生理学的浸水プロフィールの増加 (45. 0%から85. 0%,p=0. 008).
- HRは変化せず,患者は有害事象や臨床的に有意な高血圧を経験しなかった.
結論:
- 抗CGRP mAbsは,EMの初期治療において臨床的に重要な血圧上昇を誘導しませんでした.
- 治療は夜間DBPの改善と浸水プロフィールの好ましい変化と関連していました.
- この結果は,抗CGRPmAbsの短期的な心血管安全性を示唆し,さらなる長期的な研究が必要である.
関連する概念動画
Holter Monitor: 24-Hour Monitoring
251
Holter monitoring is a continuous electrocardiography (ECG) recording that tracks the heart's electrical activity over an extended period, generally 24 to 48 hours. This noninvasive diagnostic tool detects irregular heart rhythms that may not be captured during a standard ECG performed in a clinical setting.DeviceThe Holter monitor is a portable, small device connected to several electrodes on the patient's chest. These electrodes detect the heart's electrical signals and transmit them to the...
251
Chronopharmacokinetics: Circadian Rhythms and Influence on Drug Response
123
Circadian rhythms are cyclic changes that are crucial in plasma drug concentrations. Various standard circadian parameters, including core body temperature, heart rate, and other cardiovascular factors, directly impact disease states and the therapeutic response to drug therapy.
The time of drug administration is an important factor to consider, as it can influence the toxic dose of a drug. For example, a study conducted by Prins et al. in 1997 examined the effects of the timing of...
The time of drug administration is an important factor to consider, as it can influence the toxic dose of a drug. For example, a study conducted by Prins et al. in 1997 examined the effects of the timing of...
123
Measurement of Blood Pressure
1.4K
Assessing blood pressure is a standard procedure executed in virtually all medical environments. The method utilized today was established over a hundred years ago by an innovative Russian doctor, Dr. Nikolai Korotkoff. The soft ticking noise, known as Korotkoff sounds, heard while taking blood pressure readings results from turbulent blood flow within the vessels. The apparatus required for this procedure includes a sphygmomanometer, a blood pressure cuff attached to a gauge, and a...
1.4K
Hypertension III: Clinical Manifestations and Diagnostic Studies
48
Hypertension is asymptomatic and also referred to as the "silent killer" until it progresses to a severe stage or causes target organ disease. Patients may experience symptoms stemming from the strain on blood vessels and tissues in various organs or the heart's increased workload.Physical exams might show no abnormalities other than high blood pressure. Signs of vascular damage, when present, correspond to the organs supplied by the affected vessels, leading to target organ damage. For...
48
Errors occurring during blood pressure monitoring
964
Blood pressure monitoring is a crucial clinical procedure in diagnosing and managing various cardiovascular conditions. Despite its significance, the accuracy of blood pressure measurements can be compromised by multiple factors, potentially leading to either falsely high or low readings. These inaccuracies are critical as they can significantly impact patient care. So, it is vital to understand these challenges deeply and adopt strategic approaches to minimize errors.
Several factors...
Several factors...
964
Antianginal Drugs: Calcium Channel Blockers and Ranolazine
671
Angina pectoris, a primary symptom of ischemic heart disease, requires careful pharmacological interventions. In this context, calcium channel blockers (CCBs) and ranolazine have emerged as crucial pharmacotherapeutic agents, providing deep insights into the complexities of angina management.
CCBs, a diverse class that includes dihydropyridines (nifedipine) and diphenylalkylamines (verapamil and diltiazem), exert their effect by blocking calcium channels in cardiac and smooth muscle cells. This...
CCBs, a diverse class that includes dihydropyridines (nifedipine) and diphenylalkylamines (verapamil and diltiazem), exert their effect by blocking calcium channels in cardiac and smooth muscle cells. This...
671


